Trial Profile
An Open Label, Multicenter, Phase II Study of AZD9291 in Non-small Cell Lung Cancer (NSCLC) Patients Harboring T790M Mutation Who Failed EGFR TKIs and With Brain and/or Leptomeningeal Metastasis
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Sep 2019
Price :
$35
*
At a glance
- Drugs Osimertinib (Primary)
- Indications Brain metastases; Meningeal carcinomatosis; Non-small cell lung cancer
- Focus Therapeutic Use
- 10 Sep 2019 Results (n=34) presented at the 20th World Conference on Lung Cancer
- 10 Sep 2019 Results (n=34) presented at the 20th World Conference on Lung Cancer.
- 31 Aug 2018 Biomarkers information updated